Alamgir Karim was instrumental in the new discovery. Photo Courtesy of University of Houston Office of Media Relations

A flask of Houston’s rain helped answer a long-running question about the origin of cellular life.

The solution is proposed by two University of Houston scientists, William A. Brookshire Department of Chemical Engineering (UH ChBE) former grad student Aman Agrawal (now a postdoctoral researcher at University of Chicago’s Pritzker School of Molecular Engineering) and Alamgir Karim, UH Dow Chair and Welch Foundation Professor of chemical and biomolecular engineering, and director of both the International Polymer & Soft Matter Center and the Materials Engineering Program at UH. They were joined by UChicago PME Dean Emeritus Matthew Tirrell and Nobel Prize-winning biologist Jack Szostak in an article published last week in Scientific Advances.

For two decades, scientists like Szostak have hypothesized that RNA fragments were the first components of life to form in the Earth’s primordial seas 3.8 million years ago. Although DNA is an essential component of cellular life, it can’t fold proteins, making it unlikely to be the initial starting point. Since RNA can fold proteins, it could have been the catalyst for cellular growth and evolution.

The problem is that seawater molecules allow RNA to bond and change too quickly, often within minutes. Rapid dissipation means no segregation of material, and thus no evolution. Szostak himself proved in 2014 that regular seawater doesn’t allow RNA fragments to form the membranes necessary for cellular life.

Then along comes Agrawal. He wasn’t looking into the origin of life. He was an engineer studying the properties of complex liquids for his doctorate. Karim was his thesis adviser and introduced Agrawal to Tirrell, who brought up the RNA problem over a lunch and some theories about how if the water was distilled it may have solved it. Where would you get distilled water 3.8 billion years ago?

“I spontaneously said ‘rainwater,’” says Karim. “His eyes lit up and he was very excited at the suggestion. So, you can say it was a spontaneous combustion of ideas or ideation.”

Using RNA samples from Szostak, they saw that distilled water increased the differences in exchange rate between samples from minutes to days, long enough for the RNA to begin mutation.

Distilled lab water is nothing like prehistoric rain, though. Luckily, a typical Houston downpour occurred during the research. Agrawal and fellow UH graduate student, Anusha Vonteddu ran outside with beakers to collect some. The samples again formed meshy walls, separating the RNA and possibly showing how life began from these fragments billions of years ago.

“The molecules we used to build these protocells are just models until more suitable molecules can be found as substitutes,” Agrawal said. “While the chemistry would be a little bit different, the physics will remain the same.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.